Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany.
Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany.
J Infect Dis. 2021 Oct 13;224(7):1109-1114. doi: 10.1093/infdis/jiab355.
Whether monoclonal antibodies are able to neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern has been investigated using pseudoviruses. In this study we show that bamlanivimab, casirivimab, and imdevimab efficiently neutralize authentic SARS-CoV-2, including variant B.1.1.7 (alpha), but variants B.1.351 (beta) and P.2 (zeta) were resistant against bamlanivimab and partially resistant to casirivimab. Whether antibodies are able to neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variantshas been investigated using pseudoviruses. We show that authentic SARS-CoV-2 carrying E484K were resistant against bamlanivimab and less susceptible to casirivimab, convalescent and vaccine-elicited sera.
研究者们使用假病毒来研究单克隆抗体是否能够中和引起关注的严重急性呼吸综合征冠状病毒 2 （SARS-CoV-2）变体。本研究表明，巴伦珠单抗、卡司瑞韦单抗和依维莫司单抗能有效地中和真实的 SARS-CoV-2，包括变体 B.1.1.7（阿尔法），但变体 B.1.351（贝塔）和 P.2（泽塔）对巴伦珠单抗有抗性，对卡司瑞韦单抗部分有抗性。研究者们使用假病毒来研究单克隆抗体是否能够中和严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）变体。本研究表明，携带 E484K 的真实 SARS-CoV-2对巴伦珠单抗有抗性，对卡司瑞韦单抗的敏感性降低，对恢复期血清和疫苗诱导的血清也是如此。
